国际肿瘤学杂志 ›› 2026, Vol. 53 ›› Issue (1): 1-15.doi: 10.3760/cma.j.cn371439-20251228-00001
中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会, 中国抗癌协会肿瘤放射治疗专业委员会
收稿日期:2025-12-28
出版日期:2026-01-08
发布日期:2026-01-13
Received:2025-12-28
Online:2026-01-08
Published:2026-01-13
中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2025年版）[J]. 国际肿瘤学杂志, 2026, 53(1): 1-15.
图1
pTis-T1aN0期食管癌治疗策略[15-17] 注：ESD为内镜下黏膜下剥离术；EMR为内镜下黏膜切除术；MBM为多环黏膜切除术；SM1为黏膜下层内1/3"
图2
cT1b-2N0期食管癌治疗策略[18-19]"
图3
cT1b-2N+或cT3-4aNany期食管癌治疗策略[20-30] 注：PS评分为体力状况评分；a若达临床完全缓解（cCR），可密切随访+挽救性手术（Ⅱ级推荐，1B类证据）；b围手术期化疗须为FLOT方案（氟尿嘧啶+奥沙利铂+多西他赛）或ECF方案（表柔比星+顺铂+氟尿嘧啶）；c度伐利尤单抗"
图4
cT4bNany期食管癌治疗策略[31-33] 注：PS评分为体力状况评分；a不适于根治性同步放化疗者"
图5
远处转移食管癌治疗策略[34-48] 注：PS评分为体力状况评分；a鳞癌为3个器官内≤5个转移灶，腺癌为单个器官内≤3个转移灶或1个区域外淋巴结站转移。所有寡转移灶均应适合局部治疗，且单个器官系统中的转移瘤数量≤3个（脑转移为≤5个）"
图6
未行新辅助治疗食管癌R0术后治疗策略[49-56] 注：a高危pT2N0指存在低分化、脉管癌栓、神经侵犯、<50岁中的任一项"
图7
食管癌R1/R2切除者治疗策略[57-59]"
图8
食管癌放疗后局部复发转移者治疗策略[60-63]"
图9
食管癌患者放疗适应证[20-28,45-59,62-65]"
图10
食管癌患者放疗禁忌证或相对禁忌证[20-32,45-59,62-65]"
图11
颈段及胸上段食管癌适形计划射野分布及BEV所示肿瘤与脊髓的相对位置 A为颈段及胸上段食管癌4野共面适形照射示意图；B~E为4个照射野在BEV可见肿瘤和脊髓的相对位置，以及多叶光栅、准直器设置 注：BEV为射野方向观"
图12
胸中、下段食管癌适形计划射野分布及BEV所示肿瘤与脊髓的相对位置 A为中下段食管癌5野共面适形照射示意图；B~F为5个照射野在BEV可见肿瘤和脊髓的相对位置，以及多叶光栅、准直器设置 注：BEV为射野方向观"
表1
食管癌放疗危及器官受量推荐[88-90]"
| 器官 | 剂量约束条件 | 对应并发症风险 |
|---|---|---|
| 脊髓 | 颈段≤45 Gy，胸段脊髓≤50 Gy | 放射性脊髓病变 |
| 双肺 | V5<63%，V20≤30% | 有症状的放射性肺炎风险<20% |
| Dmean=7、13、20、24、27 Gy | 有症状的放射性肺炎风险分别为5%、10%、20%、30%、40% | |
| 心脏 | Dmean<26 Gy | 心包炎风险<15% |
| V30<46% | 心包炎风险<15% | |
| V25<10% | 远期心源性死亡风险<1% | |
| 肝脏 | Dmean<30~32 Gy | 典型放射性肝病风险<5%（适用于不存在既往肝病或肝细胞癌的患者） |
| Dmean<28 Gy | 典型放射性肝病风险<5%（适用于既往有肝脏疾病或肝细胞癌的肝功能Child-Pugh A级患者，且排除乙型肝炎病毒再激活患者） | |
| 气管 | 文献罕见关于常规分割下气管耐受剂量的报道，建议气管可耐受的最大剂量<75 Gy，并避免热点剂量（≥110%处方剂量）落入靶区内气管壁 | |
| 胃 | 受照体积为1/3、2/3、全胃的TD5/5分别为60、55和50 Gy，TD50/5分别为70、67和65 Gy | |
| D100%<45 Gy | 胃溃疡风险<7% | |
| 建议接受40 Gy的胃体积小于全部胸腔胃的40%~50% |
表2
食管癌特殊放疗技术的剂量推荐"
| 放疗技术 | 推荐剂量 | 危及器官受量 |
|---|---|---|
| 质子放疗 | 肺平均剂量<20 Gy（RBE），全肺V20<30%，心脏V40<40%，肝脏V30<30%，脊髓最大剂量<45 Gy（RBE） | |
| 新辅助治疗 | 40~50.4 Gy（RBE），常规分割 | |
| 鳞癌根治性同步放化疗 | 50.4~60 Gy（RBE），常规分割（化疗方案为氟尿嘧啶+顺铂） | |
| 腺癌根治性同步放化疗 | 中位剂量50.4 Gy（RBE）[36~63 Gy（RBE）]，常规分割（化疗方案为氟尿嘧啶+顺铂） | |
| 单纯质子治疗 | 中位剂量50~65 Gy（RBE） | |
| 辅助放疗 | 45~50.4 Gy（RBE），常规分割 | |
| 与X线联合照射 | X线中位剂量36 Gy（16.2~60 Gy，常规分割），质子中位剂量36 Gy（RBE）[17.5~54.5 Gy，2.5~3.7 Gy（RBE）/次]，常规分割 | |
| 放化疗后复发者 | 中位剂量54.0 Gy（RBE）[50.4~61.2 Gy（RBE）]，常规分割 | |
| 碳离子放疗 | 食管Dmax<60 Gy（RBE） Dmax<40 Gy（RBE）[5 Gy（RBE）/次] | |
| Ⅱ、Ⅲ期新辅助放疗 | 33.6 Gy（RBE）/8次 | |
| Ⅰ期根治性放疗 | 48~50.4 Gy（RBE）/12次 | |
| 根治术后孤立复发淋巴结 | 48 Gy（RBE）/12次 | |
| 后装腔内放疗 | 暂缺 | |
| 放疗未控不宜手术者 | 后装补量10~15 Gy，5~6 Gy/次，每周1次，共2~3次，黏膜下0.5 cm | |
| 原发灶放化疗后复发 | 外照射40~50 Gy，后装3~5 Gy/次，2~3次；或单纯后装20~40 Gy | |
| 放射性粒子植入 | 暂缺 | |
| 放疗后6个月内复发 | 100~120 Gy | |
| 放疗后6个月以上复发 | 120~160 Gy |
表3
食管癌新辅助放化疗中的推荐化疗方案"
| 方案 | 剂量及用法 | 推荐等级 |
|---|---|---|
| 首选方案 | ||
| 紫杉醇+卡铂 | 紫杉醇50 mg/m2 d1，卡铂AUC=2 d1，qw，共5周 | Ⅰ级推荐，1A类证据 |
| 顺铂+氟尿嘧啶/ 卡培他滨/替吉奥 | 顺铂75~100 mg/m2 d1、29，氟尿嘧啶750~1 000 mg/m2 qd CIV d1~4、d29~32，q5w； 或顺铂15 mg/m2 d1~5，氟尿嘧啶800 mg/m2 qd CIV 120 h，q3w，共2周期 | Ⅰ级推荐，1A类证据 |
| 顺铂30 mg/m2 d1，卡培他滨800 mg/m2 bid d1~5，qw，共5周 | ||
| 顺铂70 mg/m2 d1，替吉奥40 mg/m2 bid（最大日剂量100 mg）d1~14，q3w，共2周期 | ||
| 长春瑞滨+顺铂 | 长春瑞滨25 mg/m2 d1、8，顺铂75 mg/m2 d1或25 mg/m2 d1~4，q3w，共2周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂+氟尿嘧啶/ 卡培他滨/替吉奥（腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1， 2 400 mg/m2 CIV 46 h，q2w，共3周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂85 mg/m2 d1、15、29，卡培他滨625 mg/m2 bid d1~5，qw，共5周 | ||
| 奥沙利铂100 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w，共2周期 | ||
| 其他方案 | ||
| 多西他赛+顺铂/卡铂 | 多西他赛75 mg/m2 d1，顺铂75 mg/m2 d1，q3w，共2周期 | Ⅱ级推荐，2A类证据 |
| 多西他赛75 mg/m2 d1，卡铂AUC=5~6 d1，q3w，共2周期 | ||
| 紫杉醇+氟尿嘧啶/ 卡培他滨 | 紫杉醇45~50 mg/m2 d1，氟尿嘧啶300 mg/m2 CIV d1~5，qw，连用5周 | Ⅱ级推荐，2B类证据 |
| 紫杉醇45~50 mg/m2 d1，卡培他滨625~825 mg/m2 bid d1~5，qw，连用5周 |
表4
食管癌新辅助化疗、免疫治疗方案"
| 方案 | 剂量及用法 | 推荐等级 |
|---|---|---|
| 顺铂+氟尿嘧啶 | 顺铂80 mg/m2 d1，氟尿嘧啶1 000 mg/m2 d1~4，q3w，共2周期 | Ⅱ级推荐，2A类证据 |
| 紫杉醇+顺铂（鳞癌） | 紫杉醇150 mg/m2 d1，顺铂50 mg/m2 d1，q2w，共3周期 紫杉醇175 mg/m2 d1，顺铂75 mg/m2 d1，q3w，共2周期 | Ⅱ级推荐，2A类证据 |
| 多西他赛+顺铂+氟尿嘧啶（鳞癌） | 多西他赛70 mg/m2 d1，顺铂70 mg/m2 d1，氟尿嘧啶750 mg/m2 d1~5，q3w，共3周期 | Ⅱ级推荐，1A类证据 |
| 奥沙利铂+氟尿嘧啶类（腺癌） | 奥沙利铂85 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w，共3周期 | Ⅰ级推荐，2A类证据 |
| 奥沙利铂130 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w | Ⅰ级推荐，2A类证据 | |
| 多西他赛+奥沙利铂+亚叶酸钙+ 氟尿嘧啶（FLOT，腺癌） | 多西他赛50 mg/m2 d1，奥沙利铂85 mg/m2 d1，亚叶酸钙200 mg/m2 d1，氟尿嘧啶2 600 mg/m2 CIV d1，q2w，术前4周期+术后4周期，共8周期 | Ⅰ级推荐，1A类证据 |
| 表柔比星+顺铂+氟尿嘧啶 （ECF，腺癌） | 表柔比星50 mg/m2 d1，顺铂60 mg/m2 d1，氟尿嘧啶200 mg/m2 CIV d1~21或卡培他滨625 mg/m2 bid d1~21，q3w，术前3周期+术后3周期，共6周期 | Ⅰ级推荐，1A类证据 |
| 度伐利尤单抗+FLOT（腺癌） | 氟尿嘧啶2 600 mg/m2 d1、15，亚叶酸钙200 mg/m2 d1、15，奥沙利铂85 mg/m2 d1、15，多西他赛50 mg/m2 d1、15，q4w，度伐利尤单抗1 500 mg d1，q4w，术前术后各2周期。新辅助治疗结束后4~8周内手术，术后4~12周度伐利尤单抗巩固治疗10周期 | Ⅰ级推荐，1A类证据 |
表5
食管癌根治性放化疗中的推荐化疗方案"
| 方案 | 剂量及用法 | 推荐等级 |
|---|---|---|
| 首选方案 | ||
| 顺铂+氟尿嘧啶 | 顺铂75~100 mg/m2 d1，氟尿嘧啶750~1 000 mg/m2 CIV 96 h，q4w，同步放疗2周期，放疗后2周期 | Ⅰ级推荐，1A类证据 |
| 顺铂+卡培他滨 | 卡培他滨800 mg/m2 bid d1~5，顺铂30 mg/m2 d1，qw，共5周 | Ⅰ级推荐，1A类证据 |
| 紫杉醇+卡铂 | 紫杉醇50 mg/m2 d1，卡铂AUC=2 d1，qw，共5周 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂+氟尿嘧啶（腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w，同步放疗3周期，放疗后3周期 | Ⅰ级推荐，2A类证据 |
| 奥沙利铂+卡培他滨（腺癌） | 奥沙利铂85 mg/m2 d1、15、29，卡培他滨625 mg/m2 bid d1~5，qw，共3次，共5周 | Ⅰ级推荐，2A类证据 |
| 紫杉醇+氟尿嘧啶 | 紫杉醇50 mg/m2 d1，氟尿嘧啶300 mg/m2 CIV 96 h，qw，共5周。放疗结束后巩固2周期：紫杉醇175 mg/m2 d1，氟尿嘧啶1 800 mg/m2 CIV 72 h，q4w | Ⅰ级推荐，2A类证据 |
| 其他方案 | ||
| 多西他赛或紫杉醇+顺铂 | 多西他赛20~30 mg/m2 d1，顺铂20~30 mg/m2 d1，qw，连用5周；或多西他赛60 mg/m2 d1，顺铂60~80 mg/m2 d1，q3w，共2周期 | Ⅰ级推荐，2A类证据 |
| 紫杉醇45~50 mg/m2 d1，顺铂20 mg/m2 d1，qw，共6周期 | ||
| 顺铂+伊立替康 | 顺铂20 mg/m2 d1，伊立替康60 mg/m2 d1，qw，共6周期 | Ⅱ级推荐，2B类证据 |
| 紫杉醇+卡培他滨 | 紫杉醇45~50 mg/m2 d1，卡培他滨625~825 mg/m2 bid d1~5，qw，连用5周 | Ⅱ级推荐，2B类证据 |
| 卡培他滨单药 | 卡培他滨625 mg/m2 bid d1~5、d8~12、d15~19，q3w，同步放疗2周期，放疗后2周期 | Ⅰ级推荐，1A类证据 |
| 替吉奥单药（≥70岁者） | 替吉奥40 mg/m2 bid d1~14，q3w，同步放疗2周期，放疗后2周期 | Ⅰ级推荐，1A类证据 |
表6
食管癌术后化疗/放化疗方案"
| 方案 | 剂量及用法 | 推荐级别 |
|---|---|---|
| 顺铂+氟尿嘧啶类 | 顺铂50 mg/m2 d1，q2w，氟尿嘧啶1 000 mg/m2 CIV d1~2，术前4~6周期+术后4~6周期，共12周期 | Ⅰ级推荐，1A类证据 |
| 顺铂80 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w，共6周期 | ||
| 顺铂80 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w，共6周期 | ||
| 紫杉醇+卡铂 | 紫杉醇135~175 mg/m2 d1，卡铂AUC=5~6 d1，q3w，共6周期 | Ⅰ级推荐，1A类证据 |
| 紫杉醇+顺铂（鳞癌） | 紫杉醇150 mg/m2 d1，顺铂50 mg/m2 d1，q2w，共6周期 | Ⅰ级推荐，2A类证据 |
| 奥沙利铂+氟尿嘧啶类（腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w；或奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶2 600 mg/m2 CIV 46 h，q2w，共12周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂130 mg/m2 d1，q3w，卡培他滨1 000 mg/m2 bid d1~14，共8周期 | ||
| 奥沙利铂130 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w，共8周期 |
表7
食管癌姑息性化疗方案"
| 方案 | 剂量及用法 | 推荐级别 |
|---|---|---|
| 一线方案 | ||
| 顺铂+氟尿嘧啶/ 卡培他滨/替吉奥 | 顺铂75 mg/m2 d1，亚叶酸钙200 mg/m2 d1，氟尿嘧啶750~1 000 mg/m2 CIV d1~4，q3w；或顺铂50 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg IV d1，2 400 mg/m2 CIV 46 h，q2w | 腺癌Ⅰ级推荐，1A类证据； 鳞癌Ⅰ级推荐，2A类证据 |
| 顺铂80 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w | ||
| 顺铂80 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w | ||
| 奥沙利铂+氟尿嘧啶类 （腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w；或奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶2 400 mg/m2 CIV 46 h，q2w | Ⅰ级推荐，2A类证据 |
| 奥沙利铂130 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w | ||
| 多西他赛+顺铂+氟尿嘧啶 （腺癌） | 多西他赛40 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，顺铂40 mg/m2 d3，q2w | Ⅰ级推荐，1A类证据 |
| 多西他赛+奥沙利铂+ 氟尿嘧啶（腺癌） | 多西他赛50 mg/m2 d1，奥沙利铂85 mg/m2 d1，氟尿嘧啶2 400 mg/m2 CIV 46 h，q2w | Ⅰ级推荐，1A类证据 |
| 紫杉醇/多西他赛+ 顺铂/奈达铂 | 紫杉醇175 mg/m2 d1，顺铂75 mg/m2 d1，q3w | Ⅱ级推荐，2A类证据 |
| 紫杉醇175 mg/m2 d1，奈达铂80~100 mg/m2 d1，q3w | ||
| 多西他赛70~85 mg/m2 d1，顺铂70~75 mg/m2 d1，q3w | ||
| 多西他赛70~85 mg/m2 d1，奈达铂80~100 mg/m2 d1，q3w | ||
| 长春瑞滨+顺铂/奈达铂 | 长春瑞滨25 mg/m2 d1、8，顺铂80 mg/m2 d1，q3w | Ⅱ级推荐，2A类证据 |
| 长春瑞滨25 mg/m2 d1、8，奈达铂80~100 mg/m2 d1，q3w | ||
| 伊立替康+氟尿嘧啶/ 卡培他滨/替吉奥 | 伊立替康180 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w；或伊立替康80 mg/m2 d1，亚叶酸钙500 mg/m2 d1，氟尿嘧啶1 200 mg/m2 CIV d1，qw，连续6周后停2周（仅限于腺癌） | Ⅱ级推荐，2A类证据 |
| 卡培他滨800 mg/m2 bid d1~14，伊立替康200 mg/m2 d1，q3w | ||
| 伊立替康160 mg/m2 d1，替吉奥40~60 mg bid d1~10，q2w | ||
| 二线及以后方案 | ||
| 紫杉类单药 | 紫杉醇175 mg/m2 d1，q3w，或80 mg/m2 d1、8、15、22，q4w，或80 mg/m2 d1、8、15，q4w | 腺癌Ⅰ级推荐，1A类证据； 鳞癌Ⅱ级推荐，2A类证据 |
| 多西他赛75~100 mg/m2 d1，q3w | ||
| 紫杉醇脂质体175 mg/m2 d1，q3w | ||
| 白蛋白结合型紫杉醇100~150 mg/m2 d1、8，q3w | ||
| 伊立替康单药 | 伊立替康150~180 mg/m2 d1，q2w，或125 mg/m2 d1、8，q3w | 腺癌Ⅰ级推荐，1A类证据； 鳞癌Ⅱ级推荐，2A类证据 |
| [1] |
Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8(12): e943-e955. DOI: 10.1016/S2468-2667(23)00211-6.
pmid: 38000889 |
| [2] | Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006. |
| [3] | National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology:esophageal and esophagogastric junction cancers (version 1.2026)[EB/OL]. [2025-12-26]. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. |
| [4] | 中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南(第2版)[M]. 北京: 中国协和医科大学出版社, 2013. |
| [5] | Yang YM, Hong P, Xu WW, et al. Advances in targeted therapy for esophageal cancer[J]. Signal Transduct Target Ther, 2020, 5(1): 229. DOI: 10.1038/s41392-020-00323-3. |
| [6] | Tsutsumi S, Saeki H, Nakashima Y, et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma[J]. Cancer Sci, 2017, 108(6): 1119-1127. DOI: 10.1111/cas.13237. |
| [7] | Jayaprakasam VS, Yeh R, Ku GY, et al. Role of imaging in esophageal cancer management in 2020: update for radiologists[J]. AJR Am J Roentgenol, 2020, 215(5): 1072-1084. DOI: 10.2214/AJR.20.22791. |
| [8] | Haefliger L, Jreige M, Du Pasquier C, et al. Esophageal cancer T-staging on MRI: a preliminary study using cine and static MR sequences[J]. Eur J Radiol, 2023, 166: 111001. DOI: 10.1016/j.ejrad.2023.111001. |
| [9] | Expert Panels on Thoracic and Gastrointestinal Imaging, Raptis CA, Goldstein A, et al. ACR appropriateness criteria® staging and follow-up of esophageal cancer[J]. J Am Coll Radiol, 2022, 19(11S): S462-S472. DOI: 10.1016/j.jacr.2022.09.008. |
| [10] | Cheng F, Liu Y, Du LH, et al. Evaluation of optimal monoenergetic images acquired by dual-energy CT in the diagnosis of T staging of thoracic esophageal cancer[J]. Insights Imaging, 2023, 14(1): 33. DOI: 10.1186/s13244-023-01381-1. |
| [11] | Zopfs D, Große Hokamp N, Reimer R, et al. Value of spectral detector CT for pretherapeutic, locoregional assessment of esophageal cancer[J]. Eur J Radiol, 2021, 134: 109423. DOI: 10.1016/j.ejrad.2020.109423. |
| [12] |
Pimentel-Nunes P, Libânio D, Bastiaansen BAJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) guideline-update 2022[J]. Endoscopy, 2022, 54(6): 591-622. DOI: 10.1055/a-1811-7025.
pmid: 35523224 |
| [13] | Guan Y, Wang J, Cao F, et al. Role of clip markers placed by endoscopic ultrasonography in contouring gross tumor volume for thoracic esophageal squamous cell carcinoma: one prospective study[J]. Ann Transl Med, 2020, 8(18): 1144. DOI: 10.21037/atm-20-4030. |
| [14] |
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2): 182-188. DOI: 10.1111/his.13975.
pmid: 31433515 |
| [15] |
Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma[J]. Gastroenterology, 2019, 157(2): 382-390.e3. DOI: 10.1053/j.gastro.2019.04.017.
pmid: 31014996 |
| [16] | Lei S, Mulmi Shrestha S, Shi R. Radiofrequency ablation for early superficial flat esophageal squamous cell neoplasia: a comprehensive review[J]. Gastroenterol Res Pract, 2020, 2020: 4152453. DOI: 10.1155/2020/4152453. |
| [17] | Inoue T, Ishihara R. Photodynamic therapy for esophageal cancer[J]. Clin Endosc, 2021, 54(4): 494-498. DOI: 10.5946/ce.2020.073. |
| [18] | Kamarajah SK, Phillips AW, Hanna GB, et al. Is local endoscopic resection a viable therapeutic option for early clinical stage T1a and T1b esophageal adenocarcinoma?: a propensity-matched analysis[J]. Ann Surg, 2022, 275(4): 700-705. DOI: 10.1097/SLA.0000000000004038. |
| [19] |
Perez Holguin RA, Olecki EJ, Stahl KA, et al. Management of clinical T2N0 esophageal and gastroesophageal junction adenocarcinoma: what is the optimal treatment?[J]. J Gastrointest Surg, 2022, 26(10): 2050-2060. DOI: 10.1007/s11605-022-05441-7.
pmid: 36042124 |
| [20] |
Shapiro J, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1090-1098. DOI: 10.1016/S1470-2045(15)00040-6.
pmid: 26254683 |
| [21] | Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27): 2796-2803. DOI: 10.1200/JCO.2018.79.1483. |
| [22] | Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamouscell carcinoma: a prospective multicenter randomized clinical trial[J]. Ann Oncol, 2023, 34(2): 163-172. DOI: 10.1016/j.annonc.2022.10.508. |
| [23] | Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA, 1999, 281(17): 1623-1627. DOI: 10.1001/jama.281.17.1623. |
| [24] | Qian D, Chen X, Shang X, et al. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: a phase Ⅱ random[J]. Radiother Oncol, 2022, 174: 1-7. DOI: 10.1016/j.radonc.2022.06.015. |
| [25] |
Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2024, 404(10447): 55-66. DOI: 10.1016/S0140-6736(24)00745-1.
pmid: 38876133 |
| [26] | Yang Y, Shao R, Cao X, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: a pooled analysis of randomized clinical trials[J]. Radiother Oncol, 2024, 200: 110517. DOI: 10.1016/j.radonc.2024.110517. |
| [27] |
Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial[J]. Nat Med, 2024, 30(9): 2549-2557. DOI: 10.1038/s41591-024-03064-w.
pmid: 38956195 |
| [28] | Leong T, Smithers BM, Michael M, et al. Preoperative chemoradiotherapy for resectable gastric cancer[J]. N Engl J Med, 2024, 391(19): 1810-1821. DOI: 10.1056/NEJMoa2405195. |
| [29] | Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer[J]. N Engl J Med, 2025, 393(3): 217-230. DOI: 10.1056/NEJMoa2503701. |
| [30] | Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125. |
| [31] | Fujii Y, Daiko H, Kubo K, et al. Non-curative resection for surgical T4b esophageal cancer: esophagectomy or non-esophagectomy?[J]. Langenbecks Arch Surg, 2023, 408(1): 201. DOI: 10.1007/s00423-023-02940-2. |
| [32] | Huang TT, Li SH, Chen YH, et al. Definitive chemoradiotherapy for clinical T4b esophageal cancer—Treatment outcomes, failure patterns, and prognostic factors[J]. Radiother Oncol, 2021, 157: 56-62. DOI: 10.1016/j.radonc.2021.01.007. |
| [33] | Chau I, Cho BC, Chen M, et al. SKYSCRAPER-07: a phase Ⅲ, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)[C/OL]. (2025-10-17)[2025-12-26]. https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=skyscraper_07__a_phase_iii__randomised_study_of_at. |
| [34] |
Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836.
pmid: 34519801 |
| [35] |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2.
pmid: 34102137 |
| [36] | Kato K, Doki Y, Ogata T, et al. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)[J]. Esophagus, 2023, 20(2): 291-301. DOI:10.1007/s10388-022-00970-1. |
| [37] | Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 234-247. DOI: 10.1016/S1470-2045(21)00692-6. |
| [38] | Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4. |
| [39] | Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. DOI: 10.1200/JCO.20.01888. |
| [40] | Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase Ⅱ study[J]. Cancer Commun (Lond), 2021, 41(11): 1173-1182. DOI: 10.1002/cac2.12214. |
| [41] | Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase Ⅲ study[J]. J Clin Oncol, 2022, 40(26): 3065-3076. DOI: 10.1200/JCO.21.01926. |
| [42] | Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714. DOI: 10.1136/bmj-2021-068714. |
| [43] | Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288.e3. DOI: 10.1016/j.ccell.2022.02.007. |
| [44] |
Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial[J]. Nat Med, 2023, 29(2): 473-482. DOI: 10.1038/s41591-022-02179-2.
pmid: 36732627 |
| [45] |
Chen Y, Cheng X, Song H, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases[J]. J Thorac Dis, 2019, 11(4): 1536-1545. DOI: 10.21037/jtd.2019.03.10.
pmid: 31179097 |
| [46] | Shi Z, Zhu X, Ruan C, et al. Evaluation of Concurrent chemoradiotherapy for survival outcomes in patients with synchronous oligometastatic esophageal squamous cell carcinoma[J]. JAMA Netw Open, 2022, 5(12): e2244619. DOI:10.1001/jamanetworkopen.2022.44619. |
| [47] | Liu Q, Chen J, Lin Y, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2024, 9(1):45-55. DOI: 10.1016/S2468-1253(23)00316-3. |
| [48] | 中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会, 等. 食管癌寡转移放射治疗专家共识(2025年版)[J]. 中华放射医学与防护杂志, 2025, 45(1): 1-17. DOI: 10.3760/cma.j.cn112271-20241014-00399. |
| [49] |
Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients[J]. Ann Thorac Surg, 2003, 75(2): 331-336. DOI: 10.1016/s0003-4975(02)04401-6.
pmid: 12607634 |
| [50] | Ni W, Yu S, Xiao Z, et al. Postoperative adjuvant therapy versus surgery alone for stage ⅡB-Ⅲ esophageal squamous cell carcinoma: a phase Ⅲ randomized controlled trial[J]. Oncologist, 2021, 26(12): e2151-e2160. DOI: 10.1002/onco.13914. |
| [51] |
Shridhar R, Weber J, Hoffe SE, et al. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis[J]. J Gastrointest Surg, 2013, 17(8): 1339-1345. DOI: 10.1007/s11605-013-2192-7.
pmid: 23749498 |
| [52] | Zhang W, Liu X, Xiao Z, et al. Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage Ⅲ thoracic esophageal squamous cell carcinoma[J]. Oncol Res Treat, 2015, 38(3): 97-102. DOI: 10.1159/000375391. |
| [53] | Chen SB, Weng HR, Wang G, et al. The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2016, 142(1): 277-286. DOI: 10.1007/s00432-015-2041-z. |
| [54] | Deng W, Yang J, Ni W, et al. Postoperative radiotherapy in pathological T2-3N0M0 thoracic esophageal squamous cell carcinoma: interim report of a prospective, phase Ⅲ, randomized controlled study[J]. Oncologist, 2020, 25(4): e701-e708. DOI: 10.1634/theoncologist.2019-0276. |
| [55] | Yang J, Zhang W, Xiao Z, et al. The impact of postoperative conformal radiotherapy after radical surgery on survival and recurrence in pathologic T3N0M0 esophageal carcinoma: a propensity score-matched analysis[J]. J Thorac Oncol, 2017, 12(7): 1143-1151. DOI: 10.1016/j.jtho.2017.03.024. |
| [56] | 王玉祥, 杨琼, 何明, 等. Ⅲ期胸段食管鳞癌根治术后的复发规律[J]. 中华肿瘤杂志, 2017, 39(1): 48-55. DOI: 10.3760/cma.j.issn.0253-3766.2017.01.010. |
| [57] |
Raman V, Jawitz OK, Voigt SL, et al. The role of adjuvant therapy in patients with margin-positive (R1) esophagectomy: a national analysis[J]. J Surg Res, 2020, 249: 82-90. DOI: 10.1016/j.jss.2019.11.035.
pmid: 31926400 |
| [58] | Bott RK, Beckmann K, Zylstra J, et al. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin[J]. Br J Surg, 2020, 107(13): 1801-1810. DOI: 10.1002/bjs.11864. |
| [59] |
He H, Zhang P, Li F, et al. The role of adjuvant chemotherapy after neoadjuvant chemotherapy or chemoradiotherapy plus esophagectomy in patients with esophageal cancer: a retrospective cohort study[J]. J Gastrointest Oncol, 2022, 13(6): 2736-2748. DOI: 10.21037/jgo-22-1008.
pmid: 36636082 |
| [60] | Miyata H, Sugimura K, Kanemura T, et al. Salvage surgery for recurrent disease after definitive chemoradiotherapy for esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2022, 29(9): 5657-5665. DOI: 10.1245/s10434-022-11802-y. |
| [61] |
Faiz Z, Dijksterhuis WPM, Burgerhof JGM, et al. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy[J]. Eur J Surg Oncol, 2019, 45(6): 931-940. DOI: 10.1016/j.ejso.2018.11.002.
pmid: 30447937 |
| [62] |
Takeda K, Matsushita H, Umezawa R, et al. Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer[J]. Radiat Oncol J, 2021, 39(4): 265-269. DOI: 10.3857/roj.2021.00325.
pmid: 34986547 |
| [63] | Lan K, Chen J. Efficacy and safety of re-irradiation for locoregional esophageal squamous cell carcinoma recurrence after radiotherapy: a systematic review and meta-analysis[J]. Radiat Oncol, 2022, 17(1): 61. DOI: 10.1186/s13014-022-02019-0. |
| [64] | Liu Y, Zheng Z, Li M, et al. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: a randomized, multicenter, phase Ⅱ clinical trial[J]. Int J Cancer, 2022, 151(4): 607-615. DOI: 10.1002/ijc.34030. |
| [65] |
Ji Y, Du X, Zhu W, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial[J]. JAMA Oncol, 2021, 7(10): 1459-1466. DOI: 10.1001/jamaoncol.2021.2705.
pmid: 34351356 |
| [66] |
Zhu J, Wang Y, Sun H, et al. Surgery versus radiotherapy for limited-stage small cell esophageal carcinoma: a multicenter, retrospective, cohort study in China (ChiSCEC)[J]. Int J Surg, 2024, 110(2): 956-964. DOI: 10.1097/JS9.0000000000000912.
pmid: 37995095 |
| [67] | Mege D, Depypere L, Piessen G, et al. Surgical management of esophageal sarcoma: a multicenter European experience[J]. Dis Esophagus. 2018, 31(3): 10.1093/dote/dox146. DOI: 10.1093/dote/dox146. |
| [68] | Sun H, Zhu N, Gong L, et al. Clinicopathological features, staging classification, and clinical outcomes of esophageal melanoma: evaluation of a pooled case series[J]. Front Oncol, 2022, 12: 858145. DOI: 10.3389/fonc.2022.858145. |
| [69] | Cazzato G, Cascardi E, Colagrande A, et al. The thousand faces of malignant melanoma: a systematic review of the primary malignant melanoma of the esophagus[J]. Cancers (Basel), 2022, 14(15): 3725. DOI: 10.3390/cancers14153725. |
| [70] | Yu ZC, Wei C, Xiong F, et al. Esophageal cancer-related multiple primary cancers (MPCs)[J]. Asian J Surg, 2018, 41(5): 519-521. DOI: 10.1016/j.asjsur.2018.06.002. |
| [71] | Chen Z, Li S, He Z, et al. Clinical analysis of 117 cases with synchronous multiple primary esophageal squamous cell carcinomas[J]. Korean J Intern Med, 2021, 36(6): 1356-1364. DOI: 10.3904/kjim.2017.280. |
| [72] |
Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7): 965-974. DOI: 10.1016/S1470-2045(18)30201-8.
pmid: 29861116 |
| [73] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2024[M]. 北京: 人民卫生出版社, 2024. |
| [74] | 祝淑钗, 李巧芳, 张雪原, 等. 食管癌根治性调强放疗靶区范围对患者预后的影响[J]. 中华肿瘤杂志, 2020, 42(12): 1040-1047. DOI: 10.3760/cma.j.cn112152-20191225-00842. |
| [75] | 祝淑钗, 董辉, 沈文斌, 等. 食管癌调强放疗淋巴引流区预防照射的同期对照研究[J]. 中华放射医学与防护杂志, 2014, 34(10): 758-762. DOI: 10.3760/cma.j.issn.0254-5098.2014.10.009. |
| [76] | 祝淑钗, 董辉, 刘志坤, 等. 早期食管癌根治性放射治疗不同照射范围的比较研究[J]. 中华放射肿瘤学杂志, 2015, 24(6): 615-618. DOI: 10.3760/cma.j.issn.1004-4221.2015.06.003. |
| [77] |
Huang W, Huang Y, Sun J, et al. Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China[J]. Radiother Oncol, 2015, 116(1): 100-106. DOI: 10.1016/j.radonc.2015.06.024.
pmid: 26142269 |
| [78] |
Huang W, Li B, Gong H, et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases[J]. Radiother Oncol, 2010, 95(2): 229-233. DOI: 10.1016/j.radonc.2010.01.006.
pmid: 20189259 |
| [79] |
Cheng J, Kong L, Huang W, et al. Explore the radiotherapeutic clinical target volume delineation for thoracic esophageal squamous cell carcinoma from the pattern of lymphatic metastases[J]. J Thorac Oncol, 2013, 8(3): 359-365. DOI: 10.1097/JTO.0b013e31827e1f6d.
pmid: 23263689 |
| [80] | Ding X, Zhang J, Li B, et al. A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy[J]. Br J Radiol, 2012, 85(1019): e1110-e1119. DOI: 10.1259/bjr/12500248. |
| [81] |
Dong Y, Guan H, Huang W, et al. Precise delineation of clinical target volume for crossing-segments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases[J]. J Thorac Dis, 2015, 7(12): 2313-2320. DOI: 10.3978/j.issn.2072-1439.2015.12.10.
pmid: 26793353 |
| [82] | Li J, Chen S, Zhu G. Comparative study of computed tomography (CT) and pathological diagnosis toward mediastinal lymph node metastasis in esophageal carcinoma[J]. Rev Assoc Med Bras (1992), 2018, 64(2): 170-174. DOI: 10.1590/1806-9282.64.02.170. |
| [83] |
Huang L, Chen C, Lin M, et al. Understanding the pattern of lymph node metastasis for trans-segmental thoracic esophageal cancer to develop precise delineation of clinical target volume for radiotherapy[J]. Ann Palliat Med, 2020, 9(3): 788-794. DOI: 10.21037/apm.2020.04.10.
pmid: 32389008 |
| [84] | Wang J, Wu Y, Zhang W, et al. Elective nodal irradiation versus involved-field irradiation for stage Ⅱ-Ⅳ cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes[J]. Radiat Oncol, 2023, 18(1): 142. DOI: 10.1186/s13014-023-02332-2. |
| [85] | Zhang J, Li M, Zhang K, et al. Concurrent chemoradiotherapy of different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: a randomized, multicenter, phase Ⅲ clinical trial[J]. Cancer Commun (Lond), 2024, 44(10): 1173-1188. DOI: 10.1002/cac2.12601. |
| [86] | Liu Q, Cai XW, Wu B, et al. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy[J]. PLoS One, 2014, 9(5): e97225. DOI: 10.1371/journal.pone.0097225. |
| [87] | Zhao Q, Sun J, Zheng F, et al. Accurate location describe and management of lymph node recurrence after esophagectomy for thoracic esophageal squamous cell carcinoma: a retrospective cohort study[J]. Int J Surg, 2024, 110(6): 3440-3449. DOI: 10.1097/JS9.0000000000001242. |
| [88] | Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S42-S49. DOI: 10.1016/j.ijrobp.2009.04.095. |
| [89] | Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S10-S19. DOI: 10.1016/j.ijrobp.2009.07.1754. |
| [90] |
Lan K, Zhu J, Zhang J, et al. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy[J]. Radiother Oncol, 2020, 149: 228-235. DOI: 10.1016/j.radonc.2020.05.036.
pmid: 32474127 |
| [91] | Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis[J]. Int J Radiat Oncol Biol Phys, 2017, 99(3): 667-676. DOI: 10.1016/j.ijrobp.2017.06.2450. |
| [92] |
Routman DM, Garant A, Lester SC, et al. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer[J]. Adv Radiat Oncol, 2019, 4(1): 63-69. DOI: 10.1016/j.adro.2018.09.004.
pmid: 30706012 |
| [93] | Chang CL, Lin KC, Chen WM, et al. Comparative effectiveness of intensity-modulated proton therapy versus intensity-modulated radiotherapy for patients with inoperable esophageal squamous cell carcinoma undergoing curative-intent concurrent chemoradiotherapy[J]. J Thorac Oncol, 2024, 19(5): 818-828. DOI: 10.1016/j.jtho.2023.12.021. |
| [94] | Zhang Q, Kong L, Liu R, et al. Ion therapy guideline (version 2020)[J]. Precis Radiat Oncol, 2021, 5(2): 73-83. DOI: 10.1002/pro6.1120. |
| [95] | Li P, Fan J, Zhang K, et al. Interstitial 125I brachytherapy as a salvage treatment for refractory cervical lymph node metastasis of thoracic esophageal squamous cell carcinoma after external irradiation with a CT-guided coplanar template-assisted technique: a retrospective study[J]. Technol Cancer Res Treat, 2022, 21: 15330338221103102. DOI: 10.1177/15330338221103102. |
| [96] | 徐裕金, 朱卫国, Liao Z, 等. 同步放化疗60 Gy对比50 Gy剂量治疗不可手术食管鳞状细胞癌的多中心随机对照研究[J]. 中华医学杂志, 2020, 100(23): 1783-1788. DOI: 10.3760/cma.j.cn112137-20200303-00574. |
| [97] | Hulshof MCCM, Geijsen ED, Rozema T, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)[J]. J Clin Oncol, 2021, 39(25): 2816-2824. DOI: 10.1200/JCO.20.03697. |
| [98] |
Xie F, Liu T, Wang X, et al. Do higher radiation doses improve survival for cervical esophageal squamous cell cancer patients treated with definitive chemoradiotherapy using intensity-modulated radiotherapy? A propensity-score matched analysis[J]. J Cancer Res Ther, 2023, 19(6): 1582-1588. DOI: 10.4103/jcrt.jcrt_321_23.
pmid: 38156925 |
| [99] | You J, Zhu SC, Li JC, et al. High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial[J]. Int J Radiat Oncol Biol Phys, 2023, 115(5): 1129-1137. DOI: 10.1016/j.ijrobp.2022.11.006. |
| [100] | Qiu Y, You J, Wang K, et al. Effect of whole-course nutrition management on patients with esophageal cancer undergoing concurrent chemoradiotherapy: a randomized control trial[J]. Nutrition, 2020, 69: 110558. DOI: 10.1016/j.nut.2019.110558. |
| [101] |
Hanania AN, Mainwaring W, Ghebre YT, et al. Radiation-induced lung injury: assessment and management[J]. Chest, 2019, 156(1): 150-162. DOI: 10.1016/j.chest.2019.03.033.
pmid: 30998908 |
| [102] | Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, et al. Radiation-induced lung injury: current evidence[J]. BMC Pulm Med, 2021, 21(1): 9. DOI: 10.1186/s12890-020-01376-4. |
| [103] | Zhang Y, Li Z, Zhang J, et al. Genetic variants in MTHFR gene predict ≥2 radiation pneumonitis in esophageal squamous cell carcinoma patients treated with thoracic radiotherapy[J]. PLoS One, 2017, 12(1): e0169147. DOI: 10.1371/journal.pone.0169147. |
| [104] |
Wang H, Wei J, Zheng Q, et al. Radiation-induced heart disease: a review of classification, mechanism and prevention[J]. Int J Biol Sci, 2019, 15(10): 2128-2138. DOI: 10.7150/ijbs.35460.
pmid: 31592122 |
| [105] | Wei T, Cheng Y. The cardiac toxicity of radiotherapy—a review of characteristics, mechanisms, diagnosis, and prevention[J]. Int J Radiat Biol, 2021, 97(10): 1333-1340. DOI: 10.1080/09553002.2021.1956007. |
| [106] | 中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识(2023版)[J]. 国际肿瘤学杂志, 2023, 50(4): 193-201. DOI: 10.3760/cma.j.cn371439-20230227-00039. |
| [107] | 中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)[J]. 中华放射肿瘤学杂志, 2010, 19(3): 179-180. DOI: 10.3760/cma.j.issn.1004-4221.2010.03.001. |
| [108] | Nakajo M, Kitajima K, Kaida H, et al. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy[J]. Clin Radiol, 2020, 75(1): 79.e9-79.e18. DOI: 10.1016/j.crad.2019.09.132. |
| [109] |
Ohsawa M, Hamai Y, Emi M, et al. Tumor response in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by surgery[J]. Anticancer Res, 2020, 40(2): 1153-1160. DOI: 10.21873/anticanres.14057.
pmid: 32014968 |
| [110] | Lim CH, Park YJ, Shin M, et al. Tumor SUVs on 18F-FDG PET/CT and aggressive pathological features in esophageal squamous cell carcinoma[J]. Clin Nucl Med, 2020, 45(3): e128-e133. DOI: 10.1097/RLU.0000000000002926. |
| [111] |
Mace AG, Pai RK, Stocchi L, et al. American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer[J]. Dis Colon Rectum, 2015, 58(1): 32-44. DOI: 10.1097/DCR.0000000000000266.
pmid: 25489692 |
| [112] |
Klevebro F, Alexandersson von döbeln G, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J]. Ann Oncol, 2016, 27(4): 660-667. DOI: 10.1093/annonc/mdw010.
pmid: 26782957 |
| [113] |
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781[J]. J Clin Oncol, 2008, 26(7): 1086-1092. DOI: 10.1200/JCO.2007.12.9593.
pmid: 18309943 |
| [114] | Kleinberg LR, Catalano PJ, Forastiere AA, et al. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network randomized phase 2 trial of neoadjuvant preoperative paclitaxel/cisplatin/radiation therapy (RT) or irinotecan/cisplatin/RT in esophageal adenocarcinoma: long-term outcome and implications for trial design[J]. Int J Radiat Oncol Biol Phys, 2016, 94 (4): 738-746. DOI: 10.1016/j.ijrobp.2015.12.009. |
| [115] |
Alderson D, Cunninggham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2017, 18(9): 1249-1260. DOI: 10.1016/S1470-2045(17)30447-3.
pmid: 28784312 |
| [116] | Jin Z, Chen D, Chen M, et al. (Neo)adjuvant chemoradiotherapy is beneficial to the long-term survival of locally advanced esophageal squamous cell carcinoma: a network meta-analysis[J]. World J Surg, 2022, 46(1): 136-146. DOI: 10.1007/s00268-021-06301-2. |
| [117] |
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011, 29(13): 1715-1721. DOI: 10.1200/JCO.2010.33.0597.
pmid: 21444866 |
| [118] |
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J]. Ann Surg Oncol, 2012, 19(1): 68-74. DOI: 10.1245/s10434-011-2049-9.
pmid: 21879261 |
| [119] | Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase2 part of a multicentre, open-label, randomised phase 2/3 trial[J]. Lancet Oncol, 2016, 17(12): 1697-1708. DOI: 10.1016/S1470-2045(16)30531-9. |
| [120] | Jing SW, Qin JJ, Liu Q, et al. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis[J]. Future Oncol, 2019, 15(20): 2413-2422. DOI: 10.2217/fon-2019-0024. |
| [121] | Faron M, Cheugoua-Zanetsie M, Tierney J, et al. Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastroesophageal junction carcinoma[J]. J Clin Oncol, 2023, 41(28): 4535-4547. DOI: 10.1200/JCO.22.02279. |
| [122] | Iwase H, Shimada M, Tsuzuki T, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase Ⅱ trial[J]. Oncology, 2013, 84 (6): 342-349. DOI: 10.1159/000348383. |
| [123] |
Yamada Y, Higuchi K, Nishuikawa K, et al. Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer[J]. Ann Oncol, 2015, 26 (1): 141-148. DOI: 10.1093/annonc/mdu472.
pmid: 32018495 |
| [124] |
Joseph DM, Malik MI, Jonnadula J, et al. Chemoradiation with weekly paclitaxel and carboplatin in esophageal squamous cell carcinoma: a prospective study[J]. South Asian J Cancer, 2021, 10(3): 151-154. DOI: 10.1055/s-0041-1727067.
pmid: 34938676 |
| [125] | Zhang XF, Liu PY, Zhang SJ, et al. Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma[J]. World J Clin Cases, 2022, 10(35): 12804-12811. DOI: 10.12998/wjcc.v10.i35.12804. |
| [126] | Ruppert BN, Watkins JM, Shirai K, et al. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer[J]. Am J Clin Oncol, 2010, 33(4): 346-352. DOI: 10.1097/COC.0b013e3181aaca26. |
| [127] |
Chen Y, Ye J, Zhu Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase Ⅲ clinical trial[J]. J Clin Oncol, 2019, 37 (20): 1695-1703. DOI: 10.1200/JCO.18.02122.
pmid: 30920880 |
| [128] | Jia R, Shan T, Zheng A, et al. Capecitabine or capecitabine plus oxaliplatin versus fluorouracil plus cisplatin in definitive concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (CRTCOESC): a multicenter, randomized, open-label, phase 3 trial[J]. J Clin Oncol, 2024, 42(20): 2436-2445. DOI: 10.1200/JCO.23.02009. |
| [129] | Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomyn (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15 (12): 1389-1396. DOI: 10.1016/S1470-2045(14)70473-5. |
| [130] | Zhang L, Li W, Lyu X, et al. Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma[J]. Chin J Cancer Res, 2017, 29(2): 149-155. DOI: 10.21147/j.issn.1000-9604.2017.02.08. |
| [131] | Xiao X, Hong HG, Zeng X, et al. The efficacy of neoadjuvant versus adjuvant therapy for resectable esophageal cancer patients: a systematic review and meta-analysis[J]. World J Surg, 2020, 44(12): 4161-4174. DOI: 10.1007/s00268-020-05721-w. |
| [132] | Al-Batran SE, Hartmann JT, Probst S, et al. Phase Ⅲ trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie[J]. J Clin Oncol, 2008, 26(9): 1435-1442. DOI: 10.1200/JCO.2007.13.9378. |
| [133] | Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase Ⅲ noninferiority trial[J]. Ann Oncol, 2009, 20(4): 666-673. DOI: 10.1093/annonc/mdn717. |
| [134] | Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase Ⅱ study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium[J]. J Clin Oncol, 2015, 33(33): 3874-3879. DOI: 10.1200/JCO.2015.60.7465. |
| [135] | Ilson DH, Forastiere A, Arquette M, et al. A phase Ⅱ trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus[J]. Cancer J, 2000, 6(5): 316-323. |
| [136] |
Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase Ⅲ study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire encologie) study[J]. J Clin Oncol, 2014, 32(31): 3520-3526. DOI: 10.1200/JCO.2013.54.1011.
pmid: 25287828 |
| [137] |
Conroy T, Etienne PL, Adenis A, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival[J]. Ann Oncol, 2002, 13(5):721-729. DOI: 10.1093/annonc/mdf063.
pmid: 12075740 |
| [138] |
Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial[J]. Lancet Oncol, 2014, 15(1): 78-86. DOI: 10.1016/S1470-2045(13)70549-7.
pmid: 24332238 |
| [139] | Wang HY, Yao ZH, Tang H, et al. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma[J]. Onco Targets Ther, 2016, 23(9): 5663-5669. DOI: 10.2147/OTT.S108580. |
| [140] | Sym SJ, Hong J, Park J, et al. A randomized phase Ⅱ study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy[J]. Cancer Chemother Pharmacol, 2013, 71(2): 481-488. DOI: 0.1007/s00280-012-2027-3. |
| [141] | Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. DOI: 10.1016/S0140-6736(10)61121-X. |
| [142] |
Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet, 2023, 402(10418): 2197-2208. DOI: 10.1016/S0140-6736(23)02033-0.
pmid: 37871604 |
| [143] | Grieb BC, Agarwal R. HER2-directed therapy in advanced gastric and gastroesophageal adenocarcinoma: triumphs and troubles[J]. Curr Treat Options Oncol, 2021, 22(10): 88. DOI: 10.1007/s11864-021-00884-7. |
| [144] |
Elena E, Jaffer A, Howard B, et al. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2025, 26(7): 847-859. DOI: 10.1016/S1470-2045(25)00287-6.
pmid: 40473445 |
| [145] | Lee KW, Bai LY, Jung M, et al. Phase 1b/2 study of zanidatamab in combination with tislelizumab and chemotherapy in first-line HER2-positive gastric/gastroesophageal junction adenocarcinoma[J/OL]. Clin Cancer Res, 2025, (2025-12-01)[2025-12-26]. https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-24-4295/770325/Phase-1b-2-Study-of-Zanidatamab-in-Combination. DOI: 10.1158/1078-0432.CCR-24-4295. [published online ahead of print]. |
| [146] | Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J]. N Engl J Med, 2020, 382(25): 2419-2430. DOI: 10.1056/NEJMoa2004413. |
| [147] | Zhao CH, Zhao J, Chen YG, et al. Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase Ⅱ study (KC-WISE 01)[J]. Cancer Commun (Lond). 2025, 45(12): 1755-1759. DOI: 10.1002/cac2.70080. |
| [148] |
Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial[J]. Nat Med, 2023, 29(8): 2133-2141. DOI: 10.1038/s41591-023-02465-7.
pmid: 37524953 |
| [149] |
Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2023, 401(10389): 1655-1668. DOI: 10.1016/S0140-6736(23)00620-7.
pmid: 37068504 |
| [150] | Huang J, Xiao J, Fang W, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial[J]. Cancer Med, 2021, 10(5): 1681-1689. DOI: 10.1002/cam4.3771. |
| [151] | Li N, Wu T, Hong YG, et al. A multi-center, single-arm, phase Ⅱ study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma[J]. BMC Med, 2022, 20(1): 472. DOI: 10.1186/s12916-022-02649-x |
| [152] | Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13): 1448-1454. DOI: 10.1200/JCO.2015.63.5995. |
| [153] | Hong Y, Liu J, Lu P, et al. Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study[J]. Oncologist, 2025, 30(3): oyae245. DOI: 10.1093/oncolo/oyae245. |
| [154] | Xu RH, Zhang Y, Pan H, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1015-1024. DOI: 10.1016/S2468-1253(21)00313-7. |
| [155] |
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235. DOI: 10.1016/S1470-2045(14)70420-6.
pmid: 25240821 |
| [156] |
Wang F, Shen L, Guo W, et al. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial[J]. Nat Med, 2024, 30(8): 2189-2198. DOI: 10.1038/s41591-024-02989-6.
pmid: 38824242 |
| [157] | Fan C, Liu F, He C, et al. Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, phase Ⅱ clinical trial[J]. Br J Cancer, 2025, 133(6): 823-830. DOI: 10.1038/s41416-025-03101-6. |
| [158] | Meng XR, Yang XL, Hong YG, et al. Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): a single-arm, multicenter, open-label phase Ⅱ clinical trial[J]. J Clin Oncol, 2024, 42(16_Suppl): e16035. DOI: 10.1200/JCO.2024.42.16_suppl.e16035. |
| [159] | Li N, Xia J, Gao X, et al. First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study[J]. Signal Transduct Target Ther, 2024, 9(1): 303. DOI: 10.1038/s41392-024-02008-7. |
| [160] | Wang X, Feng GJ, Fu CR, et al. Preliminary results of the ALTER-E009 study: efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—a multicenter, multi-cohort retrospective exploratory study[J]. J Clin Oncol, 2025, 43(Suppl_4): 361(2025). DOI: 10.1200/JCO.2025.43.4_suppl.361. |
| [161] |
Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018, 36(1): 61-67. DOI: 10.1200/JCO.2017.74.9846.
pmid: 29116900 |
| [162] |
Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018, 24(6): 1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439.
pmid: 29358502 |
| [163] |
Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018, 36(28): 2836-2844. DOI: 10.1200/JCO.2017.76.6212.
pmid: 30110194 |
| [164] |
Gao X, Xu N, Li Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial[J]. Lancet Oncol, 2023, 24(10): 1134-1146. DOI: 10.1016/S1470-2045(23)00411-4.
pmid: 37797632 |
| [165] | Sun H, Yang W, Luo J, et al. Safety and tolerability of neoadjuvant radiotherapy combined with anti-PD-1 antibody toripalimab for locally advanced, resectable esophageal squamous cell cancer: a prospective phase ⅠB trial[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3 Suppl): S102-S103. DOI: 10.1016/j.ijrobp.2021.07.238. |
| [166] | Zhang W, Yan C, Zhang T, et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study[J]. Oncoimmunology, 2021, 10(1): 1971418. DOI: 10.1080/2162402X.2021.1971418. |
| [167] |
He W, Leng X, Mao T, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma[J]. Oncologist, 2022, 27(1): e18-e28. DOI: 10.1093/oncolo/oyab011.
pmid: 35305102 |
| [168] |
Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2023, 24(5): 483-495. DOI: 10.1016/S1470-2045(23)00108-0.
pmid: 37080222 |
| [169] |
Li J, Chen Z, Bai Y, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study[J]. Nat Med, 2024, 30(3): 740-748. DOI: 10.1038/s41591-024-02797-y.
pmid: 38302715 |
| [170] | Zhang XT, Wang JF, Wang G, et al. LBA79 GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase Ⅲ study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma[J]. Ann Oncol, 2023, 34(Suppl_2): S1319. DOI: 10.1016/j.annonc.2023.10.080. |
| [171] | Ji JF, Shen L, Li ZY, et al. CT006-Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (COMPASSION-15): a randomized, double blind, phase 3 trial[C/OL]// AACR Annual Meeting 2024, San Diego, California, AACR 2024: Oral CT006. [2025-12-26]. https://www.abstractsonline.com/pp8/#!/20272/session/660 |
| [172] | Chen R, Liu Q, Li Q, et al. A phase Ⅱ clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)[J]. EClinicalMedicine, 2023, 62: 102118. DOI: 10.1016/j.eclinm.2023.102118. |
| [173] |
Zhu Y, Wen J, Li Q, et al. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial[J]. Lancet Oncol, 2023, 24(4): 371-382. DOI: 10.1016/S1470-2045(23)00060-8.
pmid: 36990609 |
| [174] | Chen B, Liu S, Zhu Y, et al. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab[J]. Nat Commun, 2024, 15(1): 1919. DOI: 10.1038/s41467-024-46307-7. |
| [175] | Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial[J]. BMJ, 2024, 385: e078876. DOI: 10.1136/bmj-2023-078876. |
| [176] | Peng L, Wang JF, Zhang YQ, et al. Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)[C/OL]// ESMO Congress 2024, Barcelona, Spain, 2024 ESMO Mini oral session: LBA60. (2024-09-16)[2025-12-26]. https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/presentation/list?q=LBA60. |
| [177] | Leng X, Lv J, Gong L, et al. 486eTiP Interim results and ctDNA biomarker analysis from the phase Ⅲ SCIENCE trial: neoadjuvant chemotherapy or chemoradiotherapy with/without sintilimab for resectable locally advanced esophageal squamous cell carcinoma[J]. Ann Oncol, 36(Suppl_4): S 1939. DOI: 10.1016/j.annonc.2025.10.312. |
| [178] | Peng F, Wu JL, Lian HM, et al. Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase Ⅱ trial[J]. Nat Commun, 2025, 16(1): 10292. DOI: 10.1038/s41467-025-65206-z. |
| [179] |
Wang H, Mu X, He H, et al. Cancer radiosensitizers[J]. Trends Pharmacol Sci, 2018, 39(1): 24-48. DOI: 10.1016/j.tips.2017.11.003.
pmid: 29224916 |
| [180] | 康梅, 权循凤. 食管癌放疗增敏剂的临床研究[J]. 国际肿瘤学杂志, 2015, 42(12): 932-935. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.013. |
| [181] | Li W, Chen P, Zhang N, et al. Endostatin and oxaliplatin-based chemoradiotherapy for inoperable esophageal squamous cell carcinoma: results of a phase Ⅱ study[J]. Oncologist, 2019, 24(4): 461-e136. DOI: 10.1634/theoncologist.2019-0119. |
| [182] | 秦尚彬, 王雅棣, 杨俊泉, 等. 甘氨双唑钠胸段食管鳞癌放射增敏作用——Ⅲ期多中心随机对照研究[J]. 中华放射肿瘤学杂志, 2012, 21(5): 426-429. DOI: 10.3760/cma.j.issn.1004-4221.2012.05.009. |
| [183] |
Lyu J, Li T, Xie C, et al. Enteral nutrition in esophageal cancer patients treated with radiotherapy: a Chinese expert consensus 2018[J]. Future Oncol, 2019, 15(5): 517-531. DOI: 10.2217/fon-2018-0697.
pmid: 30457348 |
| [184] | Xu YJ, Cheng JC, Lee JM, et al. A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy[J]. Oncologist, 2015, 20(10): 1216-1222. DOI: 10.1634/theoncologist.2015-0178. |
| [185] | Lyu J, Shi A, Li T, et al. Effects of enteral nutrition on patients with oesophageal carcinoma treated with concurrent chemoradiotherapy: a prospective, multicentre, randomised, controlled study[J]. Front Oncol, 2022, 12: 839516. DOI: 10.3389/fonc.2022.839516. |
| [186] |
Dong J, Dai Z, Cao F, et al. Effects of PEG in patients with esophageal squamous cell carcinoma during concurrent chemoradiotherapy: a prospective study[J]. Gastrointest Endosc, 2023, 98(6): 901-910.e3. DOI: 10.1016/j.gie.2023.04.2094.
pmid: 37150411 |
| [187] | 彭孟凡, 田硕, 李晨辉, 等. 食管癌发病机制及中医药临床干预研究进展[J]. 中国实验方剂学杂志, 2022, 28(12): 267-274. DOI: 10.13422/j.cnki.syfjx.20220528. |
| [188] | 岑章敏, 邓天好, 刘珍, 等. 基于“瘀、毒、虚”理论探讨潘敏求论治食管癌的经验[J]. 中医肿瘤学杂志, 2023, 5(3): 12-16. DOI: 10.19811/j.cnki.ISSN2096-6628.2023.05.003. |
| [189] | 谭滢, 朱潇雨, 李杰. 基于“诸逆冲上,皆属于火”探讨肿瘤相关性呃逆的病因病机与治法[J]. 中医杂志, 2021, 62(24): 2153-2156. DOI: 10.13288/j.11-2166/r.2021.24.008. |
| [1] | 余云鹏, 戴春华, 凌锐. 替雷利珠单抗联合化疗治疗进展期食管癌的疗效及安全性[J]. 国际肿瘤学杂志, 2026, 53(1): 31-37. |
| [2] | 程红蕾, 王体, 兰志东, 巩合义. 临床指标在食管癌新辅助治疗疗效预测中的价值[J]. 国际肿瘤学杂志, 2025, 52(9): 592-597. |
| [3] | 刘琦, 曲国斌, 朱健, 吴凡. 双能CT虚拟平扫图像代替真实平扫图像在光子与质子放疗剂量计算中的可行性研究[J]. 国际肿瘤学杂志, 2025, 52(7): 401-408. |
| [4] | 朱健. 肿瘤质子放疗剂量学特点序言[J]. 国际肿瘤学杂志, 2025, 52(7): 432-433. |
| [5] | 吴仕章, 胡漫, 戴天缘, 李成强, 陶城, 段敬豪, 陈进琥, 白曈, 孔甜, 朱健. 全中枢神经系统肿瘤1例质子放疗剂量学特点分析[J]. 国际肿瘤学杂志, 2025, 52(7): 434-440. |
| [6] | 李成强, 王云刚, 余以珊, 吴仕章, 陶城, 马星民, 戴天缘, 段敬豪, 陈进琥, 白曈, 朱健. 乳腺癌4例质子放疗剂量学特点分析[J]. 国际肿瘤学杂志, 2025, 52(7): 448-454. |
| [7] | 段敬豪, 岳金波, 陶城, 吴仕章, 李成强, 戴天缘, 陈进琥, 白曈, 朱健. 腹盆部肿瘤3例质子放疗剂量学特点分析[J]. 国际肿瘤学杂志, 2025, 52(7): 455-461. |
| [8] | 钟啸, 李步托, 王琳琳. ALK阳性NSCLC脑转移放疗的研究进展[J]. 国际肿瘤学杂志, 2025, 52(6): 374-378. |
| [9] | 伊艳, 李宝生. 食管癌个体化精准综合治疗进展[J]. 国际肿瘤学杂志, 2025, 52(5): 257-261. |
| [10] | 何文武, 韩泳涛. 食管癌外科治疗述评[J]. 国际肿瘤学杂志, 2025, 52(5): 262-267. |
| [11] | 吕晓岩, 王媛, 王军. 精准医学背景下的食管鳞状细胞癌放疗研究进展[J]. 国际肿瘤学杂志, 2025, 52(5): 268-272. |
| [12] | 文英美, 夏锦雄, 王园园, 姚颐. 放疗对抗肿瘤免疫的影响：从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236. |
| [13] | 赵彪, 朱俞朴, 张雅婷, 袁美芳, 李瀚, 杨毅, 孙朝细. 左侧乳腺癌保乳术后基于靶区内缘切线野dIMRT剂量优化策略的研究[J]. 国际肿瘤学杂志, 2025, 52(11): 689-694. |
| [14] | 李伟杰, 戴天缘, 胡漫, 吴仕章, 李成强, 陶城, 段敬豪, 陈进琥, 白曈, 魏国辉, 朱健. 头颈部肿瘤3例质子放疗剂量学特点研究[J]. 国际肿瘤学杂志, 2025, 52(10): 646-652. |
| [15] | 陶城, 范秉杰, 李成强, 吴仕章, 段敬豪, 戴天缘, 白曈, 陈进琥, 朱健. 肺癌3例质子放疗剂量学特点分析[J]. 国际肿瘤学杂志, 2025, 52(10): 653-658. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
